Pharmaceutical industry – Page 38
-
Business
Injunction blocks first US biosimilar
Despite regulatory approval, Amgen is delaying sales of Sandoz’s version of filgrastim
-
Business
FDA accused of violating drug company’s freedom of speech
Amarin says the regulator is stopping it from giving ‘truthful, not misleading’ information to doctors about its fatty acid drug
-
Business
Alexion to buy Synageva for rare disease drugs
$8.4bn deal gives firm access to enzyme drug currently under review with US and EU regulators
-
Business
Takeda offers $2.4bn to settle diabetes litigation
Aims to settle multiple outstanding lawsuits relating to Actos (pioglitazone) and bladder cancer
-
Business
Zoetis to sell or close 10 plants in cost-cutting drive
Animal health firm will slash product portfolio in a bid to save $300m annually
-
BusinessMerger creates biggest supplier of unlicensed drugs
Clinigen will buy Idis to consolidate different routes by which doctors can access medicines that are unavailable locally
-
BusinessGenerics firms in three-way takeover battle
Mylan is chasing Perrigo, while fending off advances from Teva
-
Business
Daiichi Sankyo steps out after Sun-Ranbaxy merger
Ranbaxy’s Japanese owner has sold off its stake in the merged company, but will retain its business partnership
-
Business
Generics giant Mylan offers $30 billion for Perrigo
Mylan makes ambitious takeover offer just weeks after Abbott aquisition closes
-
Business
BMS invests in gene therapy
Bristol-Myers Squibb makes $100 million deal with biotech uniQure
-
Business
Novartis accused of ‘derailing’ trials for cheap eye disease drug
BMJ says pharma giant is trying to block access to a drug that would save the NHS millions
-
Business
Horizon to acquire orphan drugs in $1.1bn Hyperion takeover
Horizon will buy Hyperion and add new drugs to its rare disease portfolio
-
Business
Sun Pharma snares Ranbaxy in $4bn deal
Acquisition makes Sun biggest drug firm in India and fifth largest generics producer in the world
-
Business
Teva buys Auspex Pharmaceuticals for $3.2bn
Generics giant will add late stage Huntingdon’s drug to CNS portfolio
-
OpinionBe careful what you wish for
Measuring R&D productivity is a thorny issue. Dennis Lendrem urges the pharmaceutical industry to learn from its mistakes.
-
Business
Valeant heads off Endo bid for Salix
Bid raised to $15.8 billion in cash after rival offer from Irish firm
-
OpinionAnalogues by catalogue
Buying in screening compounds directly feels like cutting out the synthetic chemist middleman, says Derek Lowe
-
Business23andMe jumps into drug R&D
Gene profiling firm aims to capitalise on its databank of genetic information to discover new drugs
-
-
Business
Drug firms warned to be honest with investors
Official warns of ‘significant consequences’ if companies aren’t forthcoming about their FDA interactions